Research into Anatomic stage ii breast cancer ajcc v8 spans multiple therapeutic approaches and trial phases.

11 total trials for this combination

Showing top 10 of 11 trials

Trials

NCT ID	Title	Status	Phase
NCT06058377	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	RECRUITING	—
NCT06058377	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	RECRUITING	—
NCT06058377	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	RECRUITING	—
NCT04001829	Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer	ACTIVE_NOT_RECRUITING	—
NCT05929768	Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer	RECRUITING	PHASE3
NCT04379570	Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy	ACTIVE_NOT_RECRUITING	PHASE3
NCT04457596	T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial	ACTIVE_NOT_RECRUITING	PHASE3
NCT05812807	Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab	RECRUITING	PHASE3
NCT04266249	CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy	ACTIVE_NOT_RECRUITING	PHASE2
NCT04001829	Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer	ACTIVE_NOT_RECRUITING	—

Related Pages

All Anatomic stage ii breast cancer ajcc v8 trials All trials in Chicago, United States